Antiretroviral and Antiparasitic Therapy Management in an Expatriate Patient with Loiasis and HIV: A Case Report

Riccardi N1*, Magnè F1, Saffioti C1, Dodi F1, Ferrazin A1, Ratto S1, Di Biagio A1, Viscoli C1

Division of Infectious Disease, IRCCS AOU San Martino-IST-University of Genoa-Italy

Abstract

Loa loa filariasis, endemic in Western and Central Africa, is rarely observed in Italy (about 100 cases reported between 1993 and 2013). Clinical manifestations of loiasis are different between expatriates and natives: asymptomatic infestation and eye involvement are more common in natives, while Calabar swelling, itching and urticaria are mainly seen in expatriates. Although a geographically restricted infection, it is not impossible to face loiasis among immigrants and travellers. Due to the HIV high prevalence in the same areas, also in apparent absence of risk factors or HIV related symptoms, an HIV test should be offered to people coming from these countries to detect unknown infections.

We describe a case of symptomatic loiasis in an expatriate man, who was hospitalized for loiasis and discovered to be also HIV-1-positive; in our patient, the diagnosis of HIV infection forced us to start highly-active-antiretroviral therapy (HAART) and antiparasitic treatment simultaneously.

Keywords: Loiasis; HIV; Treatment; HAART

Introduction

Loiasis, caused by the filarial nematode Loa loa, is also known as African eye-worm, because the adult worm occasionally move across the eye of infected people. Loa loa is a little diurnal nematode (male 30 × 0.4 mm, female up to 60 × 0.5 mm) that can inhabit the lymphatics and subcutaneous tissues of humans. Loiasis is a vector-borne infection and the main vectors (deerflies) are day-biting flies from two species of the genus *Chrysops*, *C. silacea* and *C. dimiduata* which harbor the infective larvae (2 mm ×25 µm) that penetrate the skin of the human host when the vector takes a blood meal. Other *Chrysops* species are of local importance, especially in the periphery of the transmission zone which is only located in Africa mainly confined, according to Rapid Assessment Procedure for Loiasis (RAPLOA) study [1], to the equatorial rain forest regions of Central and West Africa. About 90 million people live in endemic areas for loiasis and Equatorial Guinea, both in rural and in the city centers, is one of the most affected country (Figure 1). Although a geographically restricted infection, globalization, human migration and international travels to and from endemic regions are effecting the burden of loiasis around the world; about 100 cases were detected in Italy between 1993 and 2013 [2]. Most people infected with Loa loa are asymptomatic and the pathogenesis of loiasis is poorly understood. Clinical signs of loiasis may appear after five months from the infection: eye worm sign and asymptomatic infestation are more common in natives of endemic regions, while Calabar swellings, which is defined by episodic angioedema due to hypersensitive reactions to migrating adult parasites and/or microfilaria [3], pruritus and urticaria are more common in expatriates who were exposed to loiasis during adulthood. Hypereosinophilia, high antibody titres to filarial antigens and microfilaraemia are common laboratory findings [4]. According to the Center for Disease Control (CDC) diethylcarbamazine (DEC) (5-10 mg/Kg daily in divided doses for 2-4 weeks) is the treatment of choice, unfortunately it is not available in many countries and it can cause serious adverse reactions related to Loa loa high microfilarial density, including encephalopathy and death [5]. Alternative therapeutic regimen may include albendazole (400 mg bis in die), used to decrease microfilaraemia, followed by a single administration of ivermectin (200 µg/Kg orally) to kill adult worms. In Sub-Saharan Africa 24.7 million people live with HIV infection and there were 1.5 million new infection in 2013 [6]. According to UNAids, in 2014, in Equatorial Guinea there were an estimated 32,000 people living with HIV, 6.2% of the adults aged 15 to 49. Due to HIV high prevalence in endemic countries for loiasis, also in apparent absence of risk factors or HIV related symptoms, an HIV test should be offered to people coming from these countries to detect unknown infections. It is important to evaluate possible drug-drug interactions between HAART and antiparasitic treatment to avoid side effects and therapeutic failure. We describe a case of symptomatic loiasis in an expatriate man, who was hospitalized for loiasis and

Figure 1: Pruriginous skin lesions due to Loa-loa filariasis.
discovered to be also HIV-1-positive; in our patient, the diagnosis of HIV infection forced us to start highly-active-antiretroviral therapy (HAART) and antiparasitic treatment simultaneously.

Case Report

A 74 years old Italian man, who had been living since 2006 in Equatorial Guinea, was admitted to our Infectious Disease Clinic on December 15th 2014 due to itchy skin lesions at lower limbs (Figure 2), eye discomfort with detection of a worm in his conjunctiva and mild fever (37.2°C). His white blood cell count was 5730/mm3 (normal values 2-9800 mm3), IgE 483 kU/L (normal values 0-240 kU/L) and 3.4 mg/L of C-reactive protein (normal values 0-5.0 mg/L). His medical history revealed complicated malaria in 2005 and pulmonary embolism in 2011 in treatment with warfarin (2.5 mg orally once daily). On physical examination, apart from the skin lesions, nothing remarkable was noticed. Malaria rapid diagnostic test resulted negative. Serologic ELISA IgG test for filariasis, performed at the Istituto Superiore di Sanità in Rome, resulted positive. Microscopic examination of blood films performed daily at noon for 4 days revealed 22 microfilariae per 9 mL of blood; the microfilaraemia was then confirmed by the Center for Tropical Disease in Negrar, Verona, Italy. Despite the absence of any clinical sign, the patient was offered an HIV screening test according to our opt-out policy. HIV ELISA-test and HIV IMMUNOBLOT-test resulted positive; his CD4+ T cell count was 600/mmc and eosinophils count was in range (5.7%). No side effect was reported during treatment and the patient is currently in follow-up and asymptomatic [9].

Conclusion

Starting antiretroviral therapy early is becoming a milestone of HIV treatment [10], nevertheless it is mandatory to minimize side effects and avoid drug-drug interactions. Albendazole rapidly undergoes extensive first-pass metabolism in the liver generating albendazole sulfoxide, albendazole active metabolite, through CYP3A4. Ritonavir boosted protease inhibitors and non-nucleoside reverse transcriptase inhibitors (NNRTIs) may increase/decrease albendazole sulfoxide plasmatic levels due to CYP3A4 inhibition/induction. For instance, long term administration of ritonavir has the potential to reduce plasma concentrations of active albendazole [11], while protease inhibitors may increase albendazole sulfoxide plasmatic level. According to in vitro data [12], ivermectin seems to be primarily metabolized by CYP3A4 as well, suggesting that, theoretically, could be an interaction between ivermectin and NNRTIs, which may potentially decrease ivermectin levels and an interaction with protease inhibitors, which may increase ivermectin levels. There is no clinically significant interaction expected between albendazole and nucleoside reverse transcriptase inhibitors as well as between albendazole and integrase inhibitors [13]. During loiasis treatment we minimized the risk of side effects and therapeutic failure selecting emtricitabine/tenofovir disoproxil 200/245 mg orally once daily) were selected for HAART to avoid possible drug-drug interaction with albendazole [7]; similarly, the modification of anticoagulant treatment with dabigatran etexilate (150 mg orally bis in die) was necessary to avoid possible drug-drug interaction with albendazole [8]. After 4 weeks, the eosinophils dropped to 8.8%, with a concomitant decrease of HIV-RNA to 89 copies/mL. After 12 weeks HIV-1-RNA was undetectable (<50 copies/ml), CD4+ count was 670/mmc and eosinophils count was in range (5.7%). No side effect was reported during treatment and the patient is currently in follow-up and asymptomatic [9].

References


